Article
Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint…
medRxiv · 2025 · Fu, Z.; Jackson-Patel, V.; Farrand, K.; Guise, C.; Silva, S.; Dabb, A.; Lin, X.; Liu, E.; Ashoorzadeh, A.; Smaill, J. B.; Hermans, I. F.; Patterson, A. V.
Key facts
| Title | Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a TLR9 dependent manner |
|---|---|
| First author | Fu, Z.; Jackson-Patel, V.; Farrand, K.; Guise, C.; Silva, S.; Dabb, A.; Lin, X.; Liu, E.; Ashoorzadeh, A.; Smaill, J. B.; Hermans, I. F.; Patterson, A. V. |
| Journal | medRxiv |
| Published | Jan 1, 2025 |
| DOI | 10.1101/2025.02.24.635378 |
| Devices mentioned | K202641, K231013, K800781, K810863, K973350, K990827 |
| Product codes mentioned | DBM, IDO, IDW, IDZ, IEO, KDT, KEQ, KER, KES, KIM, KIO, NNK and 7 more |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1